Metrics as of 10/17/2026, 08:52 AM (Berlin time), refresh in progress.
NRx Pharmaceuticals Stock
NRx Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jonathan C. Javitt
- Employees
- 29
- Market cap
- $113 M
- IPO
- 04/12/2017
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for…
NRx Pharmaceuticals stock: price history
1D
-4.1%
1W
-8.8%
1M
-22.4%
6M
+2.0%
YTD
-4.1%
1Y
-14.5%
2Y
+111.4%
5Y
-97.5%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~31% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about NRx Pharmaceuticals
Analyst assessment of NRx Pharmaceuticals
PRICE TARGET LOW
US$2.00
CONSENSUS
US$2.00
MEDIAN
US$2.00
PRICE TARGET HIGH
US$2.00
0
STRONG BUY
5
BUY
0
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 01/10/2026
NRx Pharmaceuticals stock metrics
P/E
-3.5
P/B
-575.81
EV/EBITDA
-3.99
RETURN ON EQUITY
9,717.6%
NET MARGIN
-1,500.5%
DEBT/EQUITY
-7.33
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.4%
FLOAT SHARES
37,388,639
AVG. DAILY VOLUME (30D)
687,132
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about NRx Pharmaceuticals stock
What does NRx Pharmaceuticals do?
NRx Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jonathan C. Javitt, the company employs around 29 people.
The IPO was on 04/12/2017; the stock trades on NASDAQ under the ticker NRXP.
What do analysts say about NRx Pharmaceuticals stock?
5 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
The average price target is US$2.00, ranging from US$2.00 to US$2.00, with a median of US$2.00.
This is an external assessment, not a statement by Market Jury.
When does NRx Pharmaceuticals report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 31% stronger than usual.
Does NRx Pharmaceuticals pay a dividend?
No, NRx Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to NRx Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get NRx Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess NRx Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.